UnifiedDoseFinding0.1.10 package

Dose-Finding Methods for Non-Binary Outcomes

get_oc_gBOIN_continuous

Generate operating characteristics for finding the maximum tolerated d...

get_oc_gBOIN_TB

Generate operating characteristics for finding the maximum tolerated d...

get_oc_Ivanova_binary

Generate operating characteristics for finding the maximum tolerated d...

get_oc_Ivanova_continuous

Generate operating characteristics for finding the maximum tolerated d...

get_oc_QuasiBOIN

Generate operating characteristics for finding the maximum tolerated d...

get_oc_RQ_CRM

Generate operating characteristics for finding the maximum tolerated d...

next_gBOIN_continuous

Determine the dose for the next cohort of new patients for single-agen...

next_gBOIN_TB

Determine the dose for the next cohort of new patients for single-agen...

next_Ivanova_binary

Determine the dose for the next cohort of new patients of binary endpo...

next_Ivanova_continuous

Determine the dose for the next cohort of new patients using Inanova d...

next_QuasiBOIN

Determine the dose for the next cohort of new patients based on equiva...

next_RQ_CRM

Determine the dose for the next cohort of new patients using Quasi-CRM...

select_mtd_gBOIN_continuous

Select the maximum tolerated dose (MTD) for single agent trials using ...

select_mtd_gBOIN_TB

Select the maximum tolerated dose (MTD) defined by Toxicity Burden (TB...

select_mtd_Ivanova_binary

Select the maximum tolerated dose (MTD) of binary endpoint for single ...

select_mtd_Ivanova_continuous

Select the maximum tolerated dose (MTD) for single agent trials of con...

select_mtd_QuasiBOIN

Select the maximum tolerated dose (MTD)-defined by equivalent score (E...

select_mtd_RQ_CRM

Select the maximum tolerated dose (MTD) using Quasi-CRM design

In many phase I trials, the design goal is to find the dose associated with a certain target toxicity rate. In some trials, the goal can be to find the dose with a certain weighted sum of rates of various toxicity grades. For others, the goal is to find the dose with a certain mean value of a continuous response. This package provides the setup and calculations needed to run a dose-finding trial with non-binary endpoints and performs simulations to assess design’s operating characteristics under various scenarios. Three dose finding designs are included in this package: unified phase I design (Ivanova et al. (2009) <doi:10.1111/j.1541-0420.2008.01045.x>), Quasi-CRM/Robust-Quasi-CRM (Yuan et al. (2007) <doi:10.1111/j.1541-0420.2006.00666.x>, Pan et al. (2014) <doi:10.1371/journal.pone.0098147>) and generalized BOIN design (Mu et al. (2018) <doi:10.1111/rssc.12263>). The toxicity endpoints can be handled with these functions including equivalent toxicity score (ETS), total toxicity burden (TTB), general continuous toxicity endpoints, with incorporating ordinal grade toxicity information into dose-finding procedure. These functions allow customization of design characteristics to vary sample size, cohort sizes, target dose-limiting toxicity (DLT) rates, discrete or continuous toxicity score, and incorporate safety and/or stopping rules.

  • Maintainer: Chia-Wei Hsu
  • License: GPL-2
  • Last published: 2022-10-15